PRPO shares fell 0.3 percent following its third-quarter 2026 earnings report, underperforming the S&P 500's 0.3 percent gain. But the market's indifference obscures a company turning an operational corner—even as a going concern warning threatens to suppress the stock until management proves it can sustain growth.

Revenues hit $7.3 million, up 8.3 percent year over year. Net loss narrowed dramatically to $8,000 from $79,000. Loss per share reached essentially zero, compared with a 5-cent loss in Q3 2025. These metrics matter because they show Precipio is moving toward profitability, not circling the drain.

Pathology revenues, the company's core business, rose 5 percent to $6.3 million. Product revenues surged 40 percent to $1 million, driven by new project wins—a sign that the company's higher-margin segments are gaining traction. Gross margin expanded to 46 percent from 44 percent, reflecting pricing power and operating leverage as volumes scale.

But adjusted EBITDA declined to $0.4 million from $0.5 million. Operating expenses jumped 10.1 percent to $3.4 million, primarily from higher personnel costs and legal fees. This is the rub: growth is not yet profitable at the bottom line.

Diagnostic cases processed rose 7.6 percent to 4,582. Average revenue per case fell due to unfavorable case mix—a warning sign that PRPO may be processing higher-volume, lower-margin work.

Operating cash flow fell to $0.6 million from $0.7 million sequentially. Cash improved to $3.6 million from $2.7 million at year-end 2025—a modest buffer against the company's historical burn rate. Total liabilities sit at $6.85 million.

Management reaffirmed substantial doubt about its ability to remain a going concern over the next 12 months, citing historical losses and execution risk on its growth plan. CEO Ilan Danieli positioned the company as shifting toward "accelerating revenue growth," with distribution partnerships through Thermo Fisher, Medline, McKesson, and Cardinal Health as the vehicles for scaling product sales.

The going concern warning is real and not to be dismissed. But it also creates a dislocation: the stock likely trades at a default discount because institutional investors mechanically avoid anything flagged for solvency doubt. If PRPO can prove over the next two quarters that product revenues continue their 40 percent run rate and gross margins stay above 45 percent, the going concern risk disappears and the stock rerate sharply higher. Watch Q4 2026 results for evidence that pathology volumes stabilize and product mix improves. Until then, the risk-reward favors patient shareholders willing to bet on operational execution.